Early and rapid identification of COVID-19 patients with neutralizing type I-interferon auto-antibodies by an easily implementable algorithm
ABSTRACT Purpose Six-19% of critically ill COVID-19 patients display circulating auto-antibodies against type I interferons (IFN-AABs). Here, we establish a clinically applicable strategy for early identification of IFN-AAB-positive patients for potential subsequent clinical interventions.Methods We analysed sera of 430 COVID-19 patients with severe and critical disease from four hospitals for presence of IFN-AABs by ELISA. Binding specificity and neutralizing activity were evaluated via competition assay and virus-infection-based neutralization assay. We defined clinical parameters associated with IFN-AAB positivity. In a subgroup of critically ill patients, we analyzed effects of therapeutic plasma exchange (TPE) on the levels of IFN-AABs, SARS-CoV-2 antibodies and clinical outcome.Results The prevalence of neutralizing AABs to IFN-α and IFN-ω in COVID-19 patients was 4.2% (18/430), while being undetectable in an uninfected control cohort. Neutralizing IFN-AABs were detectable exclusively in critically affected, predominantly male (83%) patients (7.6% IFN-α and 4.6% IFN-ω in 207 patients with critical COVID-19). IFN-AABs were present early post-symptom onset and at the peak of disease. Fever and oxygen requirement at hospital admission co-presented with neutralizing IFN-AAB positivity. IFN-AABs were associated with higher mortality (92.3% versus 19.1 % in patients without IFN-AABs). TPE reduced levels of IFN-AABs in three of five patients and may increase survival of IFN-AAB-positive patients compared to those not undergoing TPE.Conclusion IFN-AABs may serve as early biomarker for development of severe COVID-19. We propose to implement routine screening of hospitalized COVID-19 patients according to our algorithm for rapid identification of patients with IFN-AABs who most likely benefit from specific therapies..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
bioRxiv.org - (2023) vom: 12. Nov. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2021.11.12.21266249 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI033015538 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI033015538 | ||
| 003 | DE-627 | ||
| 005 | 20231205150254.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211116s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.11.12.21266249 |2 doi | |
| 035 | |a (DE-627)XBI033015538 | ||
| 035 | |a (biorXiv)10.1101/2021.11.12.21266249 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Akbil, Bengisu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Early and rapid identification of COVID-19 patients with neutralizing type I-interferon auto-antibodies by an easily implementable algorithm |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Purpose Six-19% of critically ill COVID-19 patients display circulating auto-antibodies against type I interferons (IFN-AABs). Here, we establish a clinically applicable strategy for early identification of IFN-AAB-positive patients for potential subsequent clinical interventions.Methods We analysed sera of 430 COVID-19 patients with severe and critical disease from four hospitals for presence of IFN-AABs by ELISA. Binding specificity and neutralizing activity were evaluated via competition assay and virus-infection-based neutralization assay. We defined clinical parameters associated with IFN-AAB positivity. In a subgroup of critically ill patients, we analyzed effects of therapeutic plasma exchange (TPE) on the levels of IFN-AABs, SARS-CoV-2 antibodies and clinical outcome.Results The prevalence of neutralizing AABs to IFN-α and IFN-ω in COVID-19 patients was 4.2% (18/430), while being undetectable in an uninfected control cohort. Neutralizing IFN-AABs were detectable exclusively in critically affected, predominantly male (83%) patients (7.6% IFN-α and 4.6% IFN-ω in 207 patients with critical COVID-19). IFN-AABs were present early post-symptom onset and at the peak of disease. Fever and oxygen requirement at hospital admission co-presented with neutralizing IFN-AAB positivity. IFN-AABs were associated with higher mortality (92.3% versus 19.1 % in patients without IFN-AABs). TPE reduced levels of IFN-AABs in three of five patients and may increase survival of IFN-AAB-positive patients compared to those not undergoing TPE.Conclusion IFN-AABs may serve as early biomarker for development of severe COVID-19. We propose to implement routine screening of hospitalized COVID-19 patients according to our algorithm for rapid identification of patients with IFN-AABs who most likely benefit from specific therapies. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Meyer, Tim |4 aut | |
| 700 | 1 | |a Stubbemann, Paula |4 aut | |
| 700 | 1 | |a Thibeault, Charlotte |0 (orcid)0000-0002-8979-9386 |4 aut | |
| 700 | 1 | |a Staudacher, Olga |4 aut | |
| 700 | 1 | |a Niemeyer, Daniela |0 (orcid)0000-0002-1897-6365 |4 aut | |
| 700 | 1 | |a Jansen, Jenny |4 aut | |
| 700 | 1 | |a Mühlemann, Barbara |4 aut | |
| 700 | 1 | |a Doehn, Jan |4 aut | |
| 700 | 1 | |a Tabeling, Christoph |4 aut | |
| 700 | 1 | |a Nusshag, Christian |4 aut | |
| 700 | 1 | |a Hirzel, Cédric |4 aut | |
| 700 | 1 | |a Sanchez, David Sökler |4 aut | |
| 700 | 1 | |a Nieters, Alexandra |4 aut | |
| 700 | 1 | |a Lother, Achim |4 aut | |
| 700 | 1 | |a Duerschmied, Daniel |4 aut | |
| 700 | 1 | |a Schallner, Nils |4 aut | |
| 700 | 1 | |a Lieberum, Jan Nikolaus |4 aut | |
| 700 | 1 | |a August, Dietrich |4 aut | |
| 700 | 1 | |a Rieg, Siegbert |0 (orcid)0000-0001-7493-7080 |4 aut | |
| 700 | 1 | |a Falcone, Valeria |4 aut | |
| 700 | 1 | |a Hengel, Hartmut |4 aut | |
| 700 | 1 | |a Kölsch, Uwe |4 aut | |
| 700 | 1 | |a Unterwalder, Nadine |4 aut | |
| 700 | 1 | |a Hübner, Ralf-Harto |4 aut | |
| 700 | 1 | |a Jones, Terry C. |4 aut | |
| 700 | 1 | |a Suttorp, Norbert |4 aut | |
| 700 | 1 | |a Drosten, Christian |4 aut | |
| 700 | 1 | |a Warnatz, Klaus |4 aut | |
| 700 | 1 | |a Spinetti, Thibaud |4 aut | |
| 700 | 1 | |a Schefold, Joerg C. |4 aut | |
| 700 | 1 | |a Dörner, Thomas |4 aut | |
| 700 | 1 | |a Sander, Leif |4 aut | |
| 700 | 1 | |a Corman, Victor M. |0 (orcid)0000-0002-3605-0136 |4 aut | |
| 700 | 1 | |a Merle, Uta |4 aut | |
| 700 | 1 | |a Kurth, Florian |0 (orcid)0000-0002-3807-473X |4 aut | |
| 700 | 1 | |a von Bernuth, Horst |0 (orcid)0000-0002-5812-7675 |4 aut | |
| 700 | 1 | |a Meisel, Christian |0 (orcid)0000-0003-0222-991X |4 aut | |
| 700 | 1 | |a Goffinet, Christine |0 (orcid)0000-0002-3959-004X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2023) vom: 12. Nov. |
| 773 | 1 | 8 | |g year:2023 |g day:12 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.11.12.21266249 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 12 |c 11 | ||